A Randomized, Active-Controlled, Efficacy Assessor-Blinded Study to Evaluate Pharmacokinetics, Safety and Efficacy of Risankizumab in Patients from 6 to Less than 18 Years of Age with Moderate to Severe Plaque Psoriasis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 30 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Risankizumab (Primary) ; Ustekinumab (Primary)
Indications Plaque psoriasis
Focus Therapeutic Use
Acronyms OptIMMize-1
Sponsors AbbVie; AbbVie Germany

Most Recent Events

26 Oct 2024 Status changed from active, no longer recruiting to completed.
13 Nov 2023 Planned primary completion date changed from 11 Oct 2024 to 12 Feb 2024.
27 Oct 2023 Planned End Date changed from 7 Aug 2025 to 16 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight